
Avantor’s Mary Blenn outlines five considerations for biopharma supply chain localization, from customer demand visibility to cost, consistency and redundancy.
over 4 years ago
Pharmaceutical Commerce - February 2022 Issue (PDF)over 4 years ago
A Lowdown on Logisticsover 4 years ago
The Shifting Course in Logistics Supportover 4 years ago
How 3PLs Can Up Their Pharma Gameover 4 years ago
For Industry in Flux, is M&A Jolt in Store?over 4 years ago
CAR-T Therapies: Three Supply Chain Considerationsover 4 years ago
The Risk of Doubling Down on Pharmaover 4 years ago
Striving for Authentic, Transparent Track and Traceover 4 years ago
Booster Rollout Lessons for Pharmaalmost 5 years ago
Assessing Adoption of Hybrid DtP Models





